Study summary

Daraxonrasib nearly doubled survival after first chemotherapy

RASolute 302 trial · 500 people, phase 3, randomized · Published May 2026, New England Journal of Medicine; FDA approved August 26, 2026

+6.5 momedian survival: 13.2 vs 6.7 months

What was tested

Daraxonrasib, a pill that blocks active RAS proteins, against chemotherapy for metastatic pancreatic cancer that had grown after earlier treatment. More than 90% of pancreatic cancers carry a RAS mutation.

What they found

Median survival was 13.2 months vs 6.7 with chemotherapy.
Time before growth was 7.2 vs 3.6 months.
Serious side effects were less common than with chemotherapy (61.8% vs 69.6%).

What it means

The first RAS-targeted drug approved for pancreatic cancer (brand name Rasonque). Trials now test it as first treatment and after surgery.

N Engl J Med, via PubMed ↗ ← Back to the outlook

Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.